PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trials in London
3 recruitingLondon, United Kingdom
Showing 1–3 of 3 trials
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Pancreatic CancerPDAC - Pancreatic Ductal Adenocarcinoma
Imperial College London1,005 enrolled1 locationNCT05727020
Recruiting
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
Pancreatic CancerPDAC - Pancreatic Ductal Adenocarcinoma
Imperial College London6,079 enrolled1 locationNCT07243262